Melanoma medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Melanoma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Melanoma from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Melanoma medical therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Melanoma medical therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Melanoma medical therapy
CDC on Melanoma medical therapy
Melanoma medical therapy in the news
Blogs on Melanoma medical therapy
Directions to Hospitals Treating Melanoma
Risk calculators and risk factors for Melanoma medical therapy

Overview

Chemotherapy is indicated for high risk melanomas (stages > IIA) as adjuvant therapy and for metastatic disease as first-line therapy. Several single agent and combination regimens have been studied, all with modest impact on survival. All current guidelines still recommend enrollment in clinical trials over current available regimens for patients with metastatic disease. Interferon therapy is the only regimen recommended for adjuvant therapy.

Medical Therapy

Although the mainstay of therapy for melanoma is surgical excision, chemotherapy is indicated for high risk melanomas as adjuvant therapy (stages 2B-IV) and for metastatic disease as first-line therapy. Several single agent and combination regimens have been studied, all with modest impact on survival. All current guidelines still recommend enrollment in clinical trials over current available regimens for patients with metastatic disease. Below is a summary of available adjuvant and treatment regimens. Interferon therapy is the only regimen recommended for adjuvant therapy.

Chemotherapy regimens

Adjuvant therapy

1. Interferon alfa-2a (Roferon-A)
2. Interferon alfa-2b (Intron-A)
3. Peginterferon alfa-2b (Sylatron)

Metastatic or unresectable disease

• Single Agent Chemotherapy

1. Dabrafenib (Tafinlar)
2. Dacarbazine (DTIC)
3. Docetaxel (Taxotere)
4. Interleukin-2 (high dose or maintenance biotherapy)
5. Imatinib (Gleevec)
6. Ipilimumab (Yervoy)
7. Nivolumab (Opdivo)
8. Paclitaxel (Taxol)
9. Pembrolizumab (Keytruda)
10. Temozolomide (Temodar)
11. Trametinib (Mekinist)
12. Vemurafenib (Zelboraf)

• Combination Chemotherapy

1. Paclitaxel nanoparticle albumin-bound + Bevacizumab + Carboplatin (ABC)
2. Carboplatin + Paclitaxel
3. Carboplatin + Paclitaxel + nanoparticle albumin-bound
4. Carboplatin + Paclitaxel +, Sorafenib
5. Cisplatin + Dacarbazine ± Carmustine
6. Cisplatin + Dacarbazine + IL-2 + IFN alfa-2b ± Carmustine
7. Cisplatin + Paclitaxel + Dacarbazine
8. Cisplatin + Vinblastine + Dacarbazine
9. Cisplatin + Vinblastine + Dacarbazine + IL-2 + IFN alfa-2b (sequential biochemotherapy)
10. Temozolomide + Bevacizumab
11. Dabrafenib + Trametinib
12. Ipilimumab + Dacarbazine
13. Ipilimumab + Nivolumab